The 8th edition of the HPAPI Summit in Boston will unite professionals that will present the entire highly potent drug development value chain – from bench to point of outsource - and how you can enhance every stage of your potent compound development strategy.
Join Maurits Janssen Senior Director, Head of Commercial Development for the Active Pharmaceutical Ingredient at Lonza Pharma & Biotech
on Thursday 20 June 2019 at 9:00 am
and learn about best practices and infrastructure requirements that facilitate accelerated timelines for highly potent APIs and drug products
Requirements for fully-integrated service offerings in a HPAPI and cytotoxic environment
The development of drug products based on potent compounds can be quite challenging. Complications with the interface between operations in drug substance and drug product handling can also result in increased program complexity and cost. This presentation will elaborate on best practices and infrastructure requirements that facilitate accelerated timelines to clinic and market. Topics include the following:
- A case study describing the development, rapid scaling, and commercial production of HPAPI drug substance
- Integrated containment requirements for particle engineering and drug products
- Impact of supporting integrated service offerings on expansion strategies
|Maurits Janssen, PhD|
|Head of Commercial Development,|
|API Development & Manufacturing|
|Lonza Pharma & Biotech|
Dr. Janssen earned his Ph.D. in organic chemistry from Utrecht University (NL) in 1996 and subsequently fulfilled several functions with increasing responsibility in consulting, marketing and sales, and R&D.
He has more than 15 years of experience in the custom manufacturing industry and gained significant experience with highly potent active pharmaceutical ingredients (HPAPIs).
For more information click here.
Contact us to schedule a meeting with Lonza.